Fumar cigarrillos y la adhesión plaquetaria.

Same author

Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy.

Oncogenesis·2017

Same author

A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem<sup>™</sup> PT).

International journal of laboratory hematology·2017

Same author

ICSH recommendations for modified and alternate methods measuring the erythrocyte sedimentation rate.

International journal of laboratory hematology·2017

Same author

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2016

Same author

Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia.

Leukemia & lymphoma·2016

Same author

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.

Journal of thrombosis and haemostasis : JTH·2015

Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026

Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026

Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026

Same journal

Documenting hospice care.

Lancet (London, England)·2026

Same journal

After the wood chipper.

Lancet (London, England)·2026

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Videos de Experimentos Relacionados

Fumar cigarrillos y la adhesión plaquetaria.

Videos de Conceptos Relacionados

Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy.

A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem<sup>™</sup> PT).

ICSH recommendations for modified and alternate methods measuring the erythrocyte sedimentation rate.

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.

Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia.

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.

Videos de Experimentos Relacionados

Fumar cigarrillos y la adhesión plaquetaria.

Videos de Conceptos Relacionados

Artículos Relacionados

Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy.

A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem<sup>™</sup> PT).

ICSH recommendations for modified and alternate methods measuring the erythrocyte sedimentation rate.

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.

Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia.

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Documenting hospice care.

After the wood chipper.

Assisted dying and the silencing of medicine's next generation.